Medical oncology;Oncologie médicale

Revue Medicale Suisse

Volumn 1, Issue 1, 2005, Pages 59-67

  Aapro, Matti S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LETROZOLE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PREDNISONE; TAMOXIFEN; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

BRAIN TUMOR; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; HUMAN; LAPAROTOMY; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; ONCOLOGY; OSTEOLYSIS; OVARY CANCER; PANCREAS CANCER; PHYSICIAN; PROSTATE CANCER; REVIEW; SARCOMA; SOLID TUMOR; STOMACH CANCER; TESTIS TUMOR; BREAST TUMOR; COLORECTAL TUMOR; LUNG TUMOR; NEOPLASM; PATHOLOGY; QUALITY OF LIFE;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASMS; QUALITY OF LIFE;

EID: 21844444854     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Fennessy M, Bates T, MacRae K, et al. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004; 91: 699-704.
2. Winzer KJ, Sauer R, Sauerbrei W, et al. German Breast Cancer Study Group. Radiation therapy after breast-conserving surgery; first results of a randomised clinical trial in patients with low risk of recurrence. Cancer 2004; 40: 998-1005.
3. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963-70.
4. Hughes KS, Schnaper LA, Berry D, et al. Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351: 971-7.
5. Crivellari D, Price K, Gelber RD, et al. International Breast Cancer Study Group. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003; 21: 4517-23.
6. Castiglione-Gertsch M, O'Neill A, Price KN, et al. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003; 95: 1833-46.
7. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
8. Coombes RC, Hall E, Gibson LJ, et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
9. Morandi P, Rouzier R, Altundag K, et al. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: The M. D. Anderson Cancer Center evidence-based approach. Cancer 2004; 101: 1482-9.
10. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-13.
11. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial. J Clin Oncol 2004; 22: 2294-302.
12. Pico C, Martin M, Jara C, et al. GEICAM Group. Epirubicin- cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15: 79-87.
13. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Scandinavian Breast Group Trial (SBG9403). Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: A Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22: 2313-20.
14. Alba E, Martin M, Ramos M, et al. Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22: 2587-93.
15. Conte PF, Guarneri V, Bruzzi P, et al. Gruppo Oncologico Nord Ovest Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: Results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 2004; 101: 704-12.
16. Bonadonna G, Zambetti M, Moliterni A, et al. Clinical relevance of different sequencing of doxorubicin and cydophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004; 22: 1614-20.
17. Bonneterre J, Roche H, Kerbrat P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 2004; 22: 3070-9.
18. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893-901.
19. O'Brien ME, Wigler N, Inbar M, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9.
20. Land SR, Kopec JA, Yothers G, et al. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Res Treat 2004; 86: 153-64.
21. Bottomley A, Biganzoli L, Cufer T, et al. European Organization for Research and Treatment of Cancer Breast Cancer Group. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol 2004; 22: 2576-86.
22. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60.
23. Strauss GM, Herndon J, Maddaus MA, et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004 (ASCO Annual Meeting Proceedings); 22 (14S, Suppl.): 7019.
24. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non small cell lung cancer (IMSCLC) Intel-group JBR.10. J Clin Oncol 2004 (ASCO Annual Meeting Proceedings); 22 (14S, Suppl.): 7018.
25. Kato H, Ichinose Y, Ohta M, et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocardnoma of the lung. N Engl J Med 2004; 350: 1713-21.
26. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. J Clin Oncol 2004 (ASCO Annual Meeting Proceedings); 22 (145, Suppl.): 7002.
27. Chen YM, Perng RP, Shih JF, et al. A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer 2004; 90: 359-65.
28. Kubota K, Watanabe K, Kunitoh H, et al. Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22: 254-61.
29. Georgoulias V, Ardavanis A, Agelidou A, et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial. J Clin Oncol 2004; 22: 2602-9.
30. Laack E, Dickgreber N, Muller T, et al. German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: From the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004; 22: 2348-56.
31. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
32. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT I. J Clin Oncol 2004; 22: 777-84.
33. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-94.
34. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-91.
35. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15: 19-27.
36. Spiro SG, Rudd RM, Souhami RL, et al. Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-smal cell lung cancer: Improved survival without detriment to quality of life. Thorax 2004; 59: 828-36.
37. Dancey J, Shepherd FA, Gralla RJ, et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183-94.
38. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350: 2050-9.
39. Leung KL, Kwok SP, Lam SC, et al. Laparoscopic resection of rectosigmoid carcinoma: Prospective randomised trial. Lancet 2004; 363: 1187-92.
40. Janson M, Bjorholt I, Carlsson P, et al. Randomized clinical trial of the costs of open and laparoscopic surgery for colonic cancer. Br J Surg 2004; 91: 409-17.
41. Smith RE, Colangelo L, Wieand HS, et al. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004; 96: 1128-32.
42. Martenson JA Jr, Willett CG, Sargent DJ, et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: Results of intergroup protocol 0130. J Clin Oncol 2004; 22: 3277-83.
43. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
44. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
45. Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The Lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-9.
46. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resemble esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 947-54.
47. Ando N, Iizuka T, Ide H, et al. Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003; 21: 4592-6.
48. Polinder S, Homs MY, Siersema PD, et al. Dutch SIREC Study Group. Cost study of metal stent placement vs single-dose brachytherapy in the palliative treatment of oesophageal cancer. Br J Cancer 2004; 90: 2067-72.
49. Homs MY, Steyerberg EW, Eijkenboom WM, et al Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: Multicentre randomised trial. Lancet 2004; 364: 1497-504.
50. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: Who may benefit? final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-77.
51. Wu CW, Hsiung CA, Lo SS, et al. Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004; 91: 283-7.
52. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91: 586-94.
53. Imamura M, Doi R. Treatment of locally advanced pancreatic cancer: Should we resect when resectable? Pancreas 2004; 28: 293-5.
54. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10.
55. Erratum in: N Engl J Med 2004; 351: 726.
56. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22: 3776-83.
57. Homma H, Mezawa S, Doi T, et al. A comparative randomized trial of intermittent intrahepatic arterial carboplatin-versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV). Hepatogastroenterology 2004; 51: 1135-9.
58. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with ethically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-7.
59. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15-23.
60. Schroder FH, Kurth KH, Fossa SD, et al. Members of the European Organisation for the Research and Treatment of Cancer Genito-urinary Group. Earty versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study. J Urol 2004; 172: 923-7.
61. Studer UE, Hauri D, Hanselmann S, et al. Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: Results of the randomized trial SAKK 08/88. J Clin Oncol 2004; 22: 4109-18.
62. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
63. Tannock IF, de Wit R, Berry WR, et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
64. Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 2004; 22: 2546-53.
65. Tyrrell CJ, Payne H, Tammela TL, et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys 2004; 60: 476-83.
66. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethyistilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22: 3705-12.
67. Schroder FH, Whelan P, de Reijke TM, et al. Members of the EORTC Genito-Urinary Group. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the «European Organization for Research and Treatment of Cancer» (EORTC) Protocol 30892. Eur Urol 2004; 45: 457-64.
68. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hypothermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003; 21: 4270-6.
69. Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: An Italian Collaborative Study from the Mario Negri Institute, Milan, GONO (Gruppo Oncologico Nord Ovest) group and IOR (Istituto Oncologico Romagnolo) group. Br J Cancer 2004; 90: 2112-7.
70. Ten Bokkel Huinink W, Lane SR, Ross GA; International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100-3.
71. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al. Postoperative Radiation Therapy in Endometrial Carcinoma Trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004; 22: 1234-41.
72. Keys HM, Roberts JA, Brunetto VL, et al. Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 744-51.
73. Erratum in: Gynecol Oncol 2004; 94: 241-2.
74. Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol 2004; 22: 3902-8.
75. Bokemeyer C, Kollmannsberger C, Stenning S, et al. Metastatic seminoma treated with either single agent carboplatin or cispratin-based combination chemotherapy: A pooled analysis of two randomised trials. Br J Cancer 2004; 91: 683-7.
76. Thomas JM, Newton-Bishop J, A'Hern R, et al. United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network. Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-66.
77. Kleeberg UR, Suciu S, Brocker EB, et al. EORTC Melanoma Group in cooperation with the German Cancer Society (DKG). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
78. Hancock BW, Wheadey K, Harris S, et al. Adjuvant interferon in high-risk melanoma: The AIM HIGH Study-United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61.
79. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 2004; 22: 1118-25.
80. Verweij J, Casali PG, Zakberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-34.
81. Stupp R, Mason WP, Van Den Bent MJ, et al. Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. J Clin Oncol 2004 (ASCO Annual Meeting Proceedings); 22 (14S, Suppl.): 2.
82. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-8.
83. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-72.
84. Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004; 15: 700-1.
85. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandrorate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133-7.
86. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004; 171: 1537-42.
87. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized. Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-21.
88. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82.
89. Smith MR, Fallon MA, Lee H, et al. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial. J Clin Endocrinol Metab 2004; 89: 3841-6.